News

Brain Tumor Research Highlights: April 2017 Cover photo courtesy of the National Cancer Institutes (NCI) Over the years, NBTS has given more than $35 million to brain tumor research projects. We’re very proud of the impact this funding has made in advancing the neuro-oncology field closer to better treatments and ultimately a cure. And while NBTS is currently focused on driving our […] April 25, 2017

Brain Tumor Research Highlights: March 2017 > See February’s Brain Tumor Research Highlights Over the years, NBTS has given more than $35 million to brain tumor research projects. We’re very proud of the impact this funding has made in advancing the neuro-oncology field closer to better treatments and ultimately a cure. And while NBTS is currently focused on driving our flagship research […] March 30, 2017

2017 Crystal Ball: The Neuro-Oncology Field Offers Predictions & Hopes For Advances In The New Year In 2016, the neuro-oncology field made significant progress toward better treatments, and ultimately a cure, for brain tumors – from new research projects launching, to important novel scientific discoveries, as well as public policy and advocacy victories in Congress and at the White House. So what should the brain tumor community hope for and expect, now, in 2017 ? We reached out to some […] January 17, 2017

SNO-CAP: Recapping Top News from the Society for Neuro-Oncology (SNO) Annual Meeting AS has been custom since its founding, NBTS sponsors and attends the Society for Neuro-Oncology (SNO) Annual Meeting. SNO is the top professional society for neuro-oncology research and clinical care globally. This yearly conference provides breaking news, analysis, and discussion of the emerging trends and latest scientific discoveries in the field of brain tumor research […] December 19, 2016

International Low-Grade Glioma Patient Registry Low-grade gliomas (LGG), those classified as Grade II by the World Health Organization, are an understudied group of brain tumors that generally strikes patients in the prime of life. They have a lower average age at diagnosis, but fortunately have a better survival prognosis than high-grade gliomas (those classified as Grades III and IV). While […] December 16, 2016